- Phase 2 trial results using Mesoblast's allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) demonstrated rates of fusion success that were comparable to the gold standard bone autograft
- MPCs were well tolerated with no cell-related serious adverse events and no evidence of any ectopic bone formation
- At 12 months, fusion was achieved in 85.7% and 62.5% of patients in the low and high MPC treatment groups compared to 75% of patients who received bone autograft
- Significant improvements in low back pain scores and total disability index were seen in both MPC groups and were comparable to those receiving bone autograft
- Those receiving MPCs had 30-43% less blood loss during the surgical procedure than those receiving bone autograft (p less than 0.05)
- These results indicate that lumbar vertebral fusion using allogeneic MPCs is as effective as bone autograft
- Eliminating the need for an autograft bone harvest will avoid the risks of this procedure, including pain, infection and blood loss.